What primary receptor cascades and in vitro signaling axes are modulated by Tirzepatide?

Pre-clinical studies indicate Tirzepatide engages primary pathways: Co-activates both GIP and GLP-1 receptors, delivering potent synergistic cyclic AMP second messenger signaling. Possesses high affinity for the GIP receptor equal to native GIP, with balanced lower affinity for GLP-1R. Additional investigations explore cellular migration, receptor binding affinities, and kinase activation in vitro.

What is the recommended reconstitution diluent and sterile handling protocol for Tirzepatide?

Lyophilized Tirzepatide cakes must be reconstituted using Bacteriostatic 0.9% Benzyl Alcohol USP. Introduce the diluent gently along the internal glass wall under a laminar flow hood, allowing passive dissolution without mechanical vortex shear or high-velocity liquid agitation.

What are the storage temperature thresholds and solution kinetics for Tirzepatide?

Lyophilized vials require desiccated storage at -20°C desiccated (stable up to 24 months). Once reconstituted into an aqueous solvent, the peptide solution must be stored at 2°C to 8°C refrigerated; do not freeze (stable 28 days) protected from UV degradation. The laboratory stability window is High molecular weight peptide; avoid vigorous agitation during dissolution. Avoid repeated freeze-thaw cycles.

Is Tirzepatide lawful to purchase and possess for laboratory research in the United Kingdom?

Yes. Non-scheduled synthetic research peptides like Tirzepatide are entirely legal to acquire, import, and hold for bona fide laboratory experimentation in the UK. However, under Regulation 46 of the Human Medicines Regulations 2012 (SI 2012/1916), supply or marketing for human clinical administration without MHRA authorization is strictly unlawful.

UK Academic MonographMetabolic & Incretin SignalingIn Vitro Laboratory Only

Tirzepatide

Q: What is the CAS registry number, molecular formula, and mass of Tirzepatide?

Tirzepatide (Dual GIP and GLP-1 Receptor Co-Agonist 39-AA Synthetic Peptide) is indexed in the CAS Registry under #2023788-19-2. Its empirical molecular formula is C225H348N48O68 with a monoisotopic molecular weight of 4813.45 g/mol. It is cataloged under the Metabolic & Incretin Signaling research classification.

Dual GIP and GLP-1 Receptor Co-Agonist 39-AA Synthetic Peptide

PubChem Molecular SpecsValidated

CAS Registry:2023788-19-2

Chemical Formula:C225H348N48O68

Monoisotopic MW:4813.45 g/mol

PubChem CID:156588324

Primary Amino Acid Sequence (39 residues)

N-terminus → C-terminus

1Tyr

2Aib

3Glu

4Gly

5Thr

6Phe

7Thr

8Ser

9Asp

10Tyr

11Ser

12Ile

13Aib

14Leu

15Asp

16Lys

17Ile

18Ala

19Gln

20Lys(AEEAc-AEEAc-gamma-Glu-1,20-eicosanedioic acid)

21Ala

22Phe

23Val

24Gln

25Trp

26Leu

27Ile

28Ala

29Gly

30Gly

31Pro

32Ser

33Ser

34Gly

35Ala

36Pro

37Pro

38Pro

39Ser-NH2

Pre-Clinical Overview

Tirzepatide is a synthetic 39-amino-acid unimolecular dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist conjugated to a C20 fatty diacid moiety. Studied extensively in UK biochemical and pharmaceutical research for receptor affinity dynamics.

Independent Laboratory Audit

Verified UK Suppliers for Tirzepatide

5 Audited British & European Sources

Supplier	Assay Purity	Reagent Format	Dispatch Location	Notes
PharmaGrade Store	≥99.3% (HPLC)	vial	United Kingdom (Royal Mail 24)	High-purity lyophilized 5mg/10mg/15mg vials with comprehensive analytical assay sheets.
Direct Peptides	≥99.2% (HPLC)	vial	UK Hub & Europe	Research grade lyophilized peptide vials with automated mass spectrometry confirmation.
Direct Sarms	≥98.8% (HPLC)	vial	United Kingdom Express	Analytical reference standard vials tested for dual incretin receptor binding.
Peptide Works	≥99.0% (HPLC)	vial	Manchester UK Hub	Northern UK laboratory dispatched lyophilized reagent vials with sequence COA.
PharmaLab Global	≥99.5% (HPLC)	pen	London UK Hub	Triple-stage assayed vials and pre-calibrated laboratory multi-dose pen formats.

Biochemical Mechanisms of Action

Molecular Signaling Pathways

1Co-activates both GIP and GLP-1 receptors, delivering potent synergistic cyclic AMP second messenger signaling.
2Possesses high affinity for the GIP receptor equal to native GIP, with balanced lower affinity for GLP-1R.
3Stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon.
4C20 fatty diacid acylation binds human serum albumin non-covalently, extending pharmacokinetic half-life to ~5 days.

Pre-Clinical Laboratory Handling

Laboratory Evaluation Guidelines

High molecular weight (4813.45 g/mol) requiring gentle reconstitution. Used as a gold-standard dual incretin benchmark in comparative pharmacology assays.

Aseptic Dissolution & StorageUK Lab Standard

Recommended Diluent:Bacteriostatic 0.9% Benzyl Alcohol USP

Lyophilized Storage:-20°C desiccated (stable up to 24 months)

Reconstituted Storage:2°C to 8°C refrigerated; do not freeze (stable 28 days)

Solution Stability:High molecular weight peptide; avoid vigorous agitation during dissolution

Academic Biochemical Monograph

Receptor Affinity, SPPS Synthesis & Pharmacokinetics

Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for Tirzepatide.

Target ReceptorsBinding Kinetics

Primary Receptor Cascade

Dual GIP and GLP-1 Receptors (Dual Incretin Agonist)

Binding Affinity (Kd / Ki)

Ki = 0.135 nM (GIP receptor); Ki = 4.23 nM (GLP-1 receptor)

Receptor Family

Class B Secretin-like G-Protein Coupled Receptors (GPCR)

Downstream Effectors

Gs protein coupling and adenylate cyclase stimulation
Glucose-dependent insulin exocytosis in beta-cells
Suppression of postprandial glucagon secretion

SPPS MethodologyISO Criteria

Synthesis Protocol

Fmoc SPPS with orthogonal C20 fatty acid side-chain conjugation

N-Terminal / C-Terminal Mod

Free amine (H-Tyr-) · Amidated (-NH2)

Acid Cleavage Cocktail

TFA / TIS / H2O / EDT (90:2.5:2.5:5 vol/vol)

HPLC Retention Standard

RP-C18: 18.2 min (0.1% TFA / ACN linear gradient)

PharmacokineticsIn Vitro / In Vivo

Elimination Half-Life

t1/2 ≈ 5.0 days (120 hours) via C20 diacid fatty acid chain albumin binding

Primary Degradation Pathway

Proteolytic cleavage of peptide backbone and beta-oxidation of fatty acid chain

Bioavailability Profile

Extended pharmacokinetic profile (>99% bound to serum albumin)

Renal Filtration Threshold

High molecular weight complex (MW: 4,813.45 Da)

Quantitative Pre-Clinical & Clinical Evidence Matrix

Documented Biochemical Endpoints & Statistical Significance

Study Design	Cohort (n)	Measured Biological Endpoint	Statistical Significance	NCBI Citation
Double-Blind RCT	n = 2,539 human cohort (SURMOUNT-1)	Body mass reduction and cardiometabolic markers across 72 weeks	p < 0.001 vs placebo	PMID 35658024
Double-Blind RCT	n = 1,879 human cohort (SURPASS-2)	Glycemic control and non-inferiority vs selective GLP-1 monotherapy	p < 0.001	PMID 34186022

Peer-Reviewed Academic Citations

Indexed Scientific Literature

Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity

New England Journal of Medicine (2021) · Frías JP, Davies MJ, Rosenstock J, et al.

Key Finding: Demonstrated superior glycemic and weight reductions compared to selective GLP-1 mono-agonists.

PubMed PMID: 34170647

BIOCHEMICAL & REGULATORY Q&A

Curated Scientific Q&A for Tirzepatide

Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.

5 Curated Questions

Tirzepatide (Dual GIP and GLP-1 Receptor Co-Agonist 39-AA Synthetic Peptide) is indexed in the CAS Registry under #2023788-19-2. Its empirical molecular formula is C225H348N48O68 with a monoisotopic molecular weight of 4813.45 g/mol. It is cataloged under the Metabolic & Incretin Signaling research classification.

Citation Benchmark: PubChem CID 156588324; British Pharmacopoeia Appendix III

Biological Pathway Correlates

More Reagents in Metabolic & Incretin Signaling

View Pathway Hub

Mixed Pre-ClinicalCAS 221231-10-3

AOD-9604

Human Growth Hormone C-Terminal Fragment (Tyr-hGH177-191)

C78H123N23O23S21815.12 g/molMetabolic & Incretin Signaling

AOD-9604 is a synthetic hexadecapeptide analog representing the lipolytic C-terminal domain of human growth hormone (hGH 177-191) with an added tyrosine residue. Investigated in UK metabolic and adipose tissue laboratories for beta-3 adrenergic receptor signaling without diabetogenic IGF-1 elevation.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.1% (HPLC))Direct Peptides (≥99.0% (HPLC))Direct Sarms (≥98.5% (HPLC))Peptide Works (≥98.7% (HPLC))PharmaLab Global (≥99.3% (HPLC))

View Full Technical Monograph

Human Trial DataCAS 910463-68-2

Semaglutide

Acylated GLP-1 Analogue (31-AA Chain with C18 Diacid Spacer)

C187H291N45O594113.58 g/molMetabolic & Incretin Signaling

Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist modified at position 8 with alpha-aminoisobutyric acid (Aib) and acylated at Lys26 with a C18 fatty diacid chain. Studied in UK endocrinology and metabolic research as a classical mono-incretin reference standard.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.2% (HPLC))Direct Peptides (≥99.1% (HPLC))Direct Sarms (≥98.7% (HPLC))Peptide Works (≥98.9% (HPLC))PharmaLab Global (≥99.4% (HPLC))

View Full Technical Monograph